First Solar rises as Q3 sales beat estimates
U.S.-based Solar panel maker First Solar's FSLR.O shares advance 1.3% to $236.65 premarket
Co beat expectations for Q3 sales on Thursday, riding strong demand
Co to build 3.7 GW U.S. factory, with production starting end-2026, ramping up through H1 2027
FSLR posts Q3 net sales of $1.6 billion vs estimate of $1.56 billion - data compiled by LSEG
Narrowed its 2025 sales forecast to between $4.95 billion and $5.2 billion from prior view of between $4.9 billion and $5.7 billion
"Q3 was challenged by contract terminations and a supply chain issue" contributing to the lower 2025 guidance - analysts at RBC Capital Markets
Brokerage adds, FSLR is seeing pricing strength which could be more impactful to longer-term outlook
As of last close, FSLR up 32.5% YTD
Related Articles
Tesla’s 2025 Shareholder Meeting Showdown: Musk’s Leadership and Tesla’s Crossroads
TradingKey - Tesla (TSLA), the electric vehicle leader, will hold its 2025 Annual Shareholder Meeting on November 6. Dubbed by CEO Elon Musk as a moment that will “decide Tesla’s future and shape the world’s,” the event centers on one pivotal question: Will shareholders approve Musk’s proposed $1 T
What Drove the 'Black Tuesday' Sell-Off? Three Key Factors Behind the U.S. Stock Plunge
TradingKey - On November 4, 2025, U.S. markets suffered a sudden and sharp selloff — dubbed “Black Tuesday” — with the Nasdaq posting its largest single-day drop in a month. The rout unfolded amid growing economic and political instability, as a record-long government shutdown worsened systemic
IonQ Stock Price Skyrockets 300% in a Year, But Recently Drops 30%—Is IonQ Still a Buy?
Is IonQ worth buying? With a recent decline of nearly 30% over the past month, is now the time to buy? How much further could IonQ's stock rise?
Novo Nordisk Q3 Earnings Preview: New CEO, Board Overhaul — Can the U.S. Weight-Loss Market Turn Around?
TradingKey - Novo Nordisk (NVO), one of Europe’s pharmaceutical giants and a leader in the weight-loss drug race, will report its Q3 2025 earnings before market open on November 5. Wall Street expects a modest rebound from Q2’s worst growth in four years, but significant pressure on profits remains.
Palantir Q3 2025 Earnings: Blowout Performance Can’t Hide an AI Bubble， Four Growing Risks Behind a Nearly 1,000x Valuation
TradingKey – After the close of trading on November 4, “AI application King” Palantir Technologies (PLTR) reported its third-quarter earnings for fiscal year 2025. Despite a blowout quarter, surging top-line growth, and a flood of commercial orders, the stock plunged in after-hours trading.
